KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Net Income (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Net Income for 8 consecutive years, with -$13.6 million as the latest value for Q4 2025.

  • Quarterly Net Income rose 59.73% to -$13.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$59.5 million through Dec 2025, up 62.75% year-over-year, with the annual reading at -$59.5 million for FY2025, 62.75% up from the prior year.
  • Net Income hit -$13.6 million in Q4 2025 for Adaptive Biotechnologies, down from $9.5 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $9.5 million in Q3 2025 to a low of -$69.5 million in Q4 2023.
  • Historically, Net Income has averaged -$42.6 million across 5 years, with a median of -$46.9 million in 2024.
  • Biggest five-year swings in Net Income: plummeted 72.94% in 2023 and later soared 129.74% in 2025.
  • Year by year, Net Income stood at -$61.4 million in 2021, then soared by 34.53% to -$40.2 million in 2022, then tumbled by 72.94% to -$69.5 million in 2023, then surged by 51.46% to -$33.7 million in 2024, then skyrocketed by 59.73% to -$13.6 million in 2025.
  • Business Quant data shows Net Income for ADPT at -$13.6 million in Q4 2025, $9.5 million in Q3 2025, and -$25.6 million in Q2 2025.